Target Name: MIR1972-1
NCBI ID: G100302243
Review Report on MIR1972-1 Target / Biomarker Content of Review Report on MIR1972-1 Target / Biomarker
MIR1972-1
Other Name(s): MIR1972 | MicroRNA 1972-1 | hsa-mir-1972-1 | hsa-mir-1972 | microRNA 1972-1 | hsa-miR-1972

MIR1972-1: A Potential Drug Target and Biomarker

Mir1972-1 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the Mir1 family of genes, which encode for small G-protein-coupled receptors (GPCRs). GPCRs are a family of transmembrane proteins that play a crucial role in cellular signaling, and they are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling.

The discovery and characterization of MIR1972-1 comes from a study by the research group led by Dr. Xujiong Ye at the University of California, San Diego. In this study, the researchers identified MIR1972-1 as a potential drug target and biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders.

MIR1972-1 functions as a GPCR, and its function in the body is not well understood. However, studies have shown that MIR1972-1 is involved in the regulation of various cellular processes, including cell signaling, angiogenesis, and inflammation. It is also known to be involved in the regulation of pain perception and neurotransmission.

One of the reasons why MIR1972-1 is considered a potential drug target is its involvement in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms of these diseases. MIR1972-1 has been shown to be involved in the regulation of neurotransmission and cell signaling in these conditions, which suggests that it may play a role in the development and progression of these diseases.

Another potential drug target for MIR1972-1 is its involvement in cancer. Many studies have shown that MIR1972-1 is involved in the regulation of cell proliferation and angiogenesis, which are key processes that are often associated with the development and progression of cancer. Therefore, MIR1972-1 may be a useful biomarker for the detection and treatment of cancer.

MIR1972-1 has also been shown to be involved in the regulation of pain perception and neurotransmission. Studies have shown that MIR1972-1 is involved in the regulation of pain signaling in the brain, and that it may play a role in the development and treatment of chronic pain.

In addition to its potential drug target and biomarker properties, MIR1972-1 also has potential clinical applications. For example, MIR1972-1 has been shown to be involved in the regulation of insulin sensitivity and inflammation, which may be useful for the treatment of obesity and type 2 diabetes.

Overall, the discovery and characterization of MIR1972-1 as a potential drug target and biomarker for the treatment of various diseases makes it an important finding with significant implications for future clinical research. Further studies are needed to fully understand the functions of MIR1972-1 and its potential as a drug target and biomarker.

Protein Name: MicroRNA 1972-1

The "MIR1972-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1972-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2 | MIR2467 | MIR25 | MIR2681 | MIR2682 | MIR26A1 | MIR26A2 | MIR26B | MIR27A | MIR27B | MIR28 | MIR2861 | MIR2909 | MIR296 | MIR297 | MIR298 | MIR299 | MIR29A | MIR29B1 | MIR29B2 | MIR29B2CHG | MIR29C | MIR300 | MIR301A | MIR301B | MIR302A | MIR302B | MIR302C | MIR302D | MIR302E | MIR302F | MIR3059